On site of the press conference of the state medical insurance administration on the adjustment of the national medical insurance drug catalogue in 2021. Today, the State Medical Security Bureau held a press conference to announce the adjustment results of the national medical insurance drug catalogue in 2021. Huang Huabo, director of the medical service management department of the national medical insurance administration, introduced that a total of 74 drugs were added to the directory and 11 drugs were removed from the directory. From the perspective of negotiation, 67 kinds of exclusive drugs outside the catalogue were successfully negotiated, with an average price reduction of 61.71%. After adjustment, the total number of drugs in the national medical insurance drug catalogue is 2860, including 1486 kinds of Western medicine and 1374 kinds of Chinese patent medicine. There are still 892 kinds of decoction pieces of traditional Chinese medicine. This adjustment mainly has the following characteristics: First, adhere to the functional orientation of "maintaining the basic". Take the affordability of the fund as the "bottom line" that must be adhered to, and on this basis, try our best to make up for the shortcomings of drug security, focusing on "delivering carbon in the snow" rather than "icing on the cake", so as to meet the basic drug needs of the insured. The two is to support COVID-19's prevention and control. Novel coronavirus pneumonia should be paid attention to and the relevant treatment drugs should be included in the payment scope in a timely manner, so as to help prevent and control the epidemic. Third, help the "upgrading" of drug security. By guiding the appropriate competition of drugs, transferring drugs or reducing the price of drugs in the catalogue, the free fund space is used to buy drugs with higher cost performance, so as to realize the substitution and upgrading of drugs in the same treatment field. At the same time, a number of drugs for rare diseases were included in the catalogue, which greatly alleviated the economic burden of patients. Fourth, cancel the payment restrictions on some drugs and expand the beneficiary population. For the drugs newly included in this adjustment, the payment scope of most varieties shall be consistent with the instructions. At the same time, on the premise of ensuring the safety of the fund, the payment restrictions on some of the original drugs in the catalogue were also cancelled, greatly improving the accessibility and fairness of drugs. Fifth, it benefits a wide range of treatment fields. The newly included drugs accurately meet the drug needs of tumors, chronic diseases, anti infection, rare diseases, women and children, involving 21 clinical groups, and patients benefit a wide range. Huang Huabo said that since the establishment of the national medical insurance administration, it has carried out the adjustment of the national medical insurance drug directory for four consecutive years, added 507 drugs to the national medical insurance payment scope, and transferred a number of "divine drugs" and "zombie drugs" out of the directory, leading to profound changes in the drug use end. Six batches of centralized drug procurement organized by the state were carried out continuously, and the average price reduction of the selected drugs was 53%. The blue book on the progress and effectiveness of China's medical insurance drug management reform issued by the China Pharmaceutical Association shows that since 2018, the proportion of medical insurance drugs used in medical institutions has increased year by year, the dominant position has been further consolidated, and the rationality of clinical medication has been improved. The price level of commonly used drugs decreased significantly, and the drug security level of major diseases and special populations increased significantly. The speed of innovative drugs entering medical insurance has been accelerated, the cycle has been greatly shortened, and the accessibility of patients has been significantly improved. Through the "combined fist" of centralized volume procurement and directory access negotiation, the drug burden of the masses has been significantly reduced. (outlook new era)